This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Meta founder Mark Zuckerberg and his wife, pediatrician and philanthropist Priscilla Chan, announced on Wednesday plans to invest $250 million over 10 years to establish a new “biohub” in New York City focused on building a new class of cellular machines that can surveil the body and snuff out disease. The new initiative, publicly revealed at the 2023 STAT Summit and previewed exclusively to STAT, is the latest program from the Chan Zuckerberg Initiative, or CZI, a company the coup
Stephen Hemsley, the former CEO of UnitedHealth Group and its current board chair, also owns an investment firm that manages his own portfolio of UnitedHealth stock and oversees other wealthy individuals’ accounts that have held shares of companies that have direct business with or indirect ties to United. It’s an unusual arrangement for someone in such a prominent role at one of the largest health care corporations in the world, according to several experts in securities and corpo
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.
Laurie Glimcher trained at Massachusetts General Hospital. Her father was the chair of orthopedic surgery there, and her son is currently a thoracic surgeon at the hospital. But Glimcher, the CEO of the neighboring Dana-Farber Cancer Institute , has no qualms about the contentious decision to sever a 30-year partnership with Massachusetts General’s parent organization.
Laurie Glimcher trained at Massachusetts General Hospital. Her father was the chair of orthopedic surgery there, and her son is currently a thoracic surgeon at the hospital. But Glimcher, the CEO of the neighboring Dana-Farber Cancer Institute , has no qualms about the contentious decision to sever a 30-year partnership with Massachusetts General’s parent organization.
Senate Finance Committee members from both parties took aim Wednesday at insurance brokers that sell plans for large Medicare Advantage insurers. Older adults at times have more than 100 plan options, and brokers help them choose the right one. But brokers can be incentivized by large insurance companies to aggressively sell plans that are a poor fit for the Medicare beneficiaries they’re supposed to help.
Back in the 1990s, scientist Lotte Bjerre Knudsen was tasked with revitalizing a floundering program at Novo Nordisk that had been trying to harness the newly-discovered GLP-1 hormone into viable diabetes drug candidates. At the time, many of Knudsen’s bosses had already lost hope for the program. Novo’s focus, after all, was on insulin, and the naturally occurring GLP-1 hormone had too short a half-life to use as a drug.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
DALLAS — Treatments like Ozempic, Wegovy, and Mounjaro have been hailed for showing 15% to over 20% weight loss in trials, but those are just averages. In reality, there are big variations in how much weight people lose on the therapies, and it’s unclear what explains those differences. One way researchers are trying to figure this out is by focusing on genes.
The US Food and Drug Administration (FDA) has approved XPHOZAH ® (tenapanor), the first and only phosphate absorption inhibitor. Ardelyx’s first-in-class oral treatment is indicated to reduce serum phosphorus in adults with chronic kidney disease ( CKD ) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant to phosphate binder therapy.
During a nearly two-decade stint as Alnylam’s founding CEO, John Maraganore took a promising but unproven approach for treating genetic disease and built a new class of medicines and what is now a nearly $21 billion company. His next goal? Helping the next generation of budding biotech entrepreneurs. Since stepping down as Alnylam CEO in 2021, Maraganore has spent much of his time passing down his knowledge to up-and-coming biotech CEOs.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Since the early days of the pandemic, long Covid has haunted us: Even a mild acute infection might leave you with life-altering consequences. And for many, that has, sadly, turned out to be the case. While research suggests long Covid rates are falling, it still affects millions. In June 2023, 6% of Americans reported experiencing long Covid. But what if long Covid isn’t the right way to think about what they are going through?
At the age of 26, Lauren Ghazal was diagnosed with Hodgkin’s lymphoma just months into her Ph.D. program in nursing theory at New York University. She experienced firsthand how the financial burden of undergoing cancer treatment, along with the emotional and physical toll of the disease itself, can lead to overwhelming distress in patients. Now, as an assistant professor at the University of Rochester in the School of Nursing, she researches health and quality of life outcomes among young
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
More than 31,000 staff – including pharmacists, mental health practitioners and social prescribers – have been recruited to work in general practice under the Additional Roles Reimbursement Scheme (ARRS) since 2019. The total was announced today by NHS England (NHSE), alongside a video to raise awareness of the roles available to patients, after a new […] The post More than 31,000 ARRS staff recruited since 2019 appeared first on The Pharmacist.
Among drugmakers, big pharma has a reputation of being stodgy and old-fashioned, while biotech startups are seen as rife with fresher thinking — companies where innovative solutions are actually hatched and are then acquired by those older, bigger firms. But at the STAT Summit on Wednesday, Daniel Skovronsky, the chief scientific and medical officer at Eli Lilly, discussed how Lilly has been able to crack both obesity and Alzheimer’s , two areas that have long stumped drug develope
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a critical look at the mounting Ozempic panic, the case against a former meme stock, and a biotech pivot with a warm reception.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
The antibiotics crisis is a silent pandemic that threatens to knock modern society back into the medieval age of therapeutic leaches and serum therapy. A world where an accidental scratch in the rose garden can kill. Why is the supply of new antibiotics so thin, and growing thinner? A high-profile Wall Street Journal article recently highlighted what everyone knows: There is huge need but no market demand.
TZIELD (teplizumab-mzwv) has demonstrated TZIELD’s potential to slow disease progression in newly diagnosed children and adolescents with Stage 3 type 1 diabetes. Data from the Phase III PROTECT clinical trial , presented at the 2023 Annual ISPAD Conference, showed that superior beta cell preservation was observed compared to placebo. As the primary endpoint, 94.9 percent of participants in the TZIELD group maintained peak C-peptide levels ≥0.2 pmol/mL.
Good morning, everyone, and how are you today? We are doing just fine, thank you. After all, the birds are still chirping and a cool breeze is wafting by the surprisingly sedate Pharmalot campus. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
A panel of FDA advisers last month found BrainStorm’s data unconvincing. The company now says a Phase 3b study will be needed for its NurOwn cell therapy to have a shot at an approval.
The fight over drug prices is far from over. Investors in biopharma companies, who lobbied vigorously — but unsuccessfully — against allowing Medicare to negotiate drug prices, are trying a new tactic to preserve their profits. A group called the Incubate Coalition, comprising the venture capital firms that bankroll most biotech startups, is pressing US lawmakers to extend by four years the time that pills can be on the market before they become subject to price negotiations w
Integrated care boards (ICBs) do not have ‘enough’ pharmacy representation, the Health and Social Care Committee chair Steve Brine has told The Pharmacist. The former pharmacy minister and Conservative MP for Winchester also said he felt primary care networks (PCNs) were ‘way too GP dominated’. Mr Brine was speaking to The Pharmacist following an address […] The post Exclusive: Lack of pharmacy representation on ICBs, warns health committee chair appeared first on The Pharmacist.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
363 
Let's personalize your content